Valproate monotherapy in the management of generalized and partial seizures.
For decades, therapeutic tradition has promoted the concept of polypharmacy in the management of epilepsy. In recent years, however, studies have shown that, for most patients, monotherapy can provide comparable or better seizure control than administration of multiple anticonvulsants, while diminishing the potential for adverse reactions, drug interactions, and poor compliance. Valproate is an important monotherapeutic agent that is highly effective in the control of idiopathic primary and secondarily generalized epilepsies, and partial seizures that do not generalize. Comparative studies have found that valproate is at least as effective as phenytoin and carbamazepine in the treatment of generalized and partial seizures. Given the similar efficacy, other factors such as pharmacokinetics and side effects may therefore determine anticonvulsant selection for monotherapy.
D002986:Clinical Trials as Topic; D004828:Epilepsies, Partial / Q000188:drug therapy*; D004827:Epilepsy / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D012074:Remission Induction; D014635:Valproic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use*
D014635:Valproic Acid